Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Sells $376,236.90 in Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt sold 9,477 shares of the firm’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the transaction, the vice president now owns 10,149 shares in the company, valued at $402,915.30. The trade was a 48.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Supernus Pharmaceuticals Price Performance

NASDAQ SUPN opened at $38.40 on Friday. The company’s fifty day moving average is $37.36 and its two-hundred day moving average is $34.78. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $40.28. The firm has a market capitalization of $2.12 billion, a price-to-earnings ratio of 35.89 and a beta of 0.90.

Institutional Trading of Supernus Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. Barclays PLC boosted its position in shares of Supernus Pharmaceuticals by 88.3% during the 3rd quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock valued at $3,393,000 after acquiring an additional 51,005 shares in the last quarter. Segall Bryant & Hamill LLC acquired a new stake in shares of Supernus Pharmaceuticals during the 3rd quarter valued at about $791,000. Geode Capital Management LLC boosted its position in shares of Supernus Pharmaceuticals by 5.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock valued at $46,218,000 after acquiring an additional 74,438 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of Supernus Pharmaceuticals by 7.6% during the 3rd quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company’s stock valued at $987,000 after acquiring an additional 2,121 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Supernus Pharmaceuticals by 40.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 253,396 shares of the specialty pharmaceutical company’s stock valued at $7,901,000 after acquiring an additional 73,118 shares in the last quarter.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Cowen restated a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Piper Sandler restated a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Finally, Cantor Fitzgerald assumed coverage on shares of Supernus Pharmaceuticals in a research report on Monday, January 6th. They issued an “overweight” rating and a $57.00 price target on the stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.